Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NRIX Nurix Therapeutics

盘前交易 12-18 04:47:01 EST

18.21

-0.63

-3.34%

最高19.14	最低17.97	成交量179.62万
今开19.05	昨收18.84	日振幅6.21%
总市值18.46亿	流通市值15.73亿	总股本1.01亿
成交额3,274万	换手率2.08%	流通股本8,636万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":18.21,"timestamp":1766005200000,"preClose":18.84,"halted":0,"volume":1796205,"delay":0,"floatShares":86361800,"shares":101369235,"eps":-2.967657,"marketStatus":"盘前交易","change":-0.63,"latestTime":"12-18 04:47:01 EST","open":19.05,"high":19.14,"low":17.97,"amount":32744720.154930003,"amplitude":0.062102,"askPrice":21.78,"askSize":100,"bidPrice":16.66,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.967657,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766068200000},"marketStatusCode":1,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":18.21,"postHourTrading":{"tag":"盘后","latestPrice":18.54,"preClose":18.21,"latestTime":"18:14 EST","volume":228486,"amount":4160927.2966,"timestamp":1766013260539},"volumeRatio":0.9450147323150099,"impliedVol":0.7576,"impliedVolPercentile":0.3695},"requestUrl":"/m/hq/s/NRIX","defaultTab":"news","newsList":[{"id":"2590395309","title":"Nurix Therapeutics股价大涨！旗下BTK降解剂bexobrutideg获积极试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590395309","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590395309?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:52","pubTimestamp":1765248777,"startTime":"0","endTime":"0","summary":"12月9日，美国生物制药公司$Nurix Therapeutics$周一报告了旗下药物bexobrutideg在治疗血液癌症上的积极试验数据。在1b期患者队列中，早期数据显示接受剂量为600mg的bexobrutideg治疗的患者ORR为83.3%。在上个月，Truist首予Nurix Therapeutics“买入”评级，目标价为30美元;BTIG则重申对Nurix Therapeutics的“买入”评级，目标价维持在27美元。根据17位分析师给出的12个月目标价，目前分析师们对对Nurix Therapeutics的平均目标价为27.18美元，最高目标价为41美元，最低目标价则为15美元。","market":"us","thumbnail":"https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379154.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Nurix Therapeutics股价大涨！旗下BTK降解剂bexobrutideg获积极试验数据","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NRIX"],"gpt_icon":0},{"id":"1148020207","title":"Nurix Therapeutics股价因早期血癌药物试验数据大幅上涨，接近一年高点，最后上涨20.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148020207","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148020207?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:34","pubTimestamp":1765204452,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics股价因早期血癌药物试验数据大幅上涨，接近一年高点，最后上涨20.5%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"1153694626","title":"Nurix Therapeutics在第67届美国血液学会年会及展览会上发布Bexobrutideg (Nx-5948)在WaldenstrÖM巨球蛋白血症阶段1试验的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1153694626","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153694626?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:01","pubTimestamp":1765198874,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics在第67届美国血液学会年会及展览会上发布Bexobrutideg (Nx-5948)在WaldenstrÖM巨球蛋白血症阶段1试验的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"1188314236","title":"Nurix Therapeutics发布口服CBL-B抑制剂NX-1607首个人体临床试验的新转化数据，显示免疫激活与肿瘤微环境重塑","url":"https://stock-news.laohu8.com/highlight/detail?id=1188314236","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188314236?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572107,"startTime":"0","endTime":"0","summary":"11月7日，Nurix Therapeutics Inc公布了口服CBL-B抑制剂NX-1607的首个人体临床试验的新转化数据，结果显示该药物具有免疫激活作用，并能重塑肿瘤微环境。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"1146190163","title":"Nurix Therapeutics 任命生物制药领域杰出领袖 Roger Dansey 医生为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1146190163","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146190163?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:01","pubTimestamp":1762776082,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics 任命生物制药领域杰出领袖 Roger Dansey 医生为董事会成员","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"1127113807","title":"Nurix Therapeutics公布口服CBL-B抑制剂Nx-1607首次人类临床试验的新转化数据，显示免疫激活和肿瘤微环境重塑","url":"https://stock-news.laohu8.com/highlight/detail?id=1127113807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127113807?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:01","pubTimestamp":1762524107,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics公布口服CBL-B抑制剂Nx-1607首次人类临床试验的新转化数据，显示免疫激活和肿瘤微环境重塑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"1120376507","title":"Nurix启动Daybreak™关键研究，针对复发或难治性慢性淋巴细胞白血病的Bexobrutideg","url":"https://stock-news.laohu8.com/highlight/detail?id=1120376507","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120376507?lang=zh_cn&edition=full","pubTime":"2025-10-22 18:01","pubTimestamp":1761127310,"startTime":"0","endTime":"0","summary":"Nurix启动Daybreak™关键研究，针对复发或难治性慢性淋巴细胞白血病的Bexobrutideg","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2568071299","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.02%报8.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568071299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568071299?lang=zh_cn&edition=full","pubTime":"2025-09-20 03:51","pubTimestamp":1758311478,"startTime":"0","endTime":"0","summary":"北京时间2025年09月20日03时51分，Nurix Therapeutics, Inc.股票出现波动，股价急速下挫5.02%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。消息层面，截至03时51分，《巴克莱银行维持Nurix Therapeutics买入评级，维持目标价31美元》资讯为影响Nurix Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920035118a4379747&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920035118a4379747&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","NRIX","BK4539"],"gpt_icon":0},{"id":"1198497678","title":"Nurix Therapeutics Q2销售额同比大增264.34%，远超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1198497678","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198497678?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:30","pubTimestamp":1752136248,"startTime":"0","endTime":"0","summary":"7月10日，生物医药股$Nurix Therapeutics(NRIX)$盘前暴涨逾30%！该公司第二季度销售额同比大增264.34%，远超市场预期>>","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f0f9e54d7803d3bf82b30fa8895eed68","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nurix Therapeutics Q2销售额同比大增264.34%，远超市场预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRIX","BK4539","BK4139"],"gpt_icon":0},{"id":"1161625950","title":"异动解读 | 业绩超预期，Nurix Therapeutics盘前大涨28.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161625950","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161625950?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:21","pubTimestamp":1752135660,"startTime":"0","endTime":"0","summary":"周四盘前，生物技术公司Nurix Therapeutics股价大幅飙升28.60%，引发市场广泛关注。这一显著涨幅主要源于公司最新发布的季度财报远超市场预期。根据公司公告，截至5月31日的季度财报显示，Nurix Therapeutics调整后每股亏损为0.52美元，明显优于分析师平均预期的0.73美元亏损。值得注意的是，分析师对Nurix Therapeutics的评级普遍较为积极。这种积极的市场情绪，加上超预期的财报表现，共同推动了公司股价的大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f0f9e54d7803d3bf82b30fa8895eed68","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NRIX"],"gpt_icon":0},{"id":"1152122372","title":"异动解读 | 业绩超预期，Nurix Therapeutics夜盘大涨16.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152122372","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152122372?lang=zh_cn&edition=full","pubTime":"2025-07-10 15:37","pubTimestamp":1752133061,"startTime":"0","endTime":"0","summary":"生物技术公司Nurix Therapeutics在夜盘交易中股价大涨16.31%，引起投资者广泛关注。这一显著涨幅主要源于公司最新发布的季度财报超出市场预期。根据公司公告，截至5月31日的季度财报显示，Nurix Therapeutics调整后每股亏损为0.52美元，明显优于分析师平均预期的0.73美元亏损。值得注意的是，目前分析师对Nurix Therapeutics的评级普遍较为积极。这种积极的市场情绪可能进一步推动了股价的上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f0f9e54d7803d3bf82b30fa8895eed68","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NRIX"],"gpt_icon":0},{"id":"2516658359","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658359","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516658359?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:35","pubTimestamp":1741016156,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时35分，Nurix Therapeutics, Inc.股票出现异动，股价急速跳水5.18%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.36%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032335579637bcd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032335579637bcd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NRIX","LENZ"],"gpt_icon":0},{"id":"2514331683","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514331683","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514331683?lang=zh_cn&edition=full","pubTime":"2025-02-28 01:39","pubTimestamp":1740677995,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日01时39分，Nurix Therapeutics, Inc.股票出现异动，股价大幅下跌5.10%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022801395598953419&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022801395598953419&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NRIX","BK4139"],"gpt_icon":0},{"id":"2514726011","title":"Nurix Therapeutics, Inc.盘中异动 临近午盘股价大跌5.04%报16.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514726011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514726011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:38","pubTimestamp":1740501495,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时38分，Nurix Therapeutics, Inc.股票出现异动，股价大幅跳水5.04%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600381696300d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600381696300d8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NRIX","BK4139"],"gpt_icon":0},{"id":"2510353845","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.00%报17.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510353845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510353845?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:07","pubTimestamp":1739297270,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日02时07分，Nurix Therapeutics, Inc.股票出现波动，股价大幅下挫5.00%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.46%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212020751961f6c35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212020751961f6c35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","LENZ","BK4139"],"gpt_icon":0},{"id":"2509231285","title":"Nurix Therapeutics, Inc.盘中异动 大幅上涨5.00%报19.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509231285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509231285?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:24","pubTimestamp":1738776295,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时24分，Nurix Therapeutics, Inc.股票出现异动，股价急速拉升5.00%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.06%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012455a23aa149&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012455a23aa149&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NRIX","BK4139"],"gpt_icon":0},{"id":"2508178878","title":"Nurix Therapeutics, Inc.盘中异动 临近收盘急速跳水5.07%报18.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178878","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508178878?lang=zh_cn&edition=full","pubTime":"2025-02-04 04:44","pubTimestamp":1738615480,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日04时44分，Nurix Therapeutics, Inc.股票出现波动，股价大幅跳水5.07%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204044440abc15275&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204044440abc15275&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NRIX","LENZ"],"gpt_icon":0},{"id":"2507692295","title":"Nurix Therapeutics, Inc.2024财年实现净利润-1.94亿美元，同比减少34.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507692295","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507692295?lang=zh_cn&edition=full","pubTime":"2025-01-30 12:01","pubTimestamp":1738209666,"startTime":"0","endTime":"0","summary":"1月30日，Nurix Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.94亿美元，同比减少34.72%；其中营业收入为54.55百万美元，同比减少29.15%，每股基本收益为-2.88美元。机构评级：截至2025年1月30日，当前有17家机构对Nurix Therapeutics, Inc.目标价做出预测，其中目标均价为33.18美元，其中最低目标价为26.00美元，最高目标价为41.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130120118a233ed05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130120118a233ed05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","LENZ"],"gpt_icon":0},{"id":"2507659941","title":"加拿大皇家银行：维持Nurix Therapeutics(NRIX.US)评级，由优于大市调整至优于大市评级, 目标价由26.00美元调整至27.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507659941","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507659941?lang=zh_cn&edition=full","pubTime":"2025-01-30 01:36","pubTimestamp":1738172215,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Nurix Therapeutics(NRIX.US)评级，由优于大市调整至优于大市评级, 目标价由26.00美元调整至27.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30013647899048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NRIX","LENZ"],"gpt_icon":0},{"id":"2507398356","title":"小摩：维持Nurix Therapeutics(NRIX.US)评级，由增持调整至增持评级, 目标价由31.00美元调整至30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507398356","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507398356?lang=zh_cn&edition=full","pubTime":"2025-01-29 22:04","pubTimestamp":1738159446,"startTime":"0","endTime":"0","summary":"小摩：维持Nurix Therapeutics(NRIX.US)评级，由增持调整至增持评级, 目标价由31.00美元调整至30.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29220447898251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NRIX","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.0714},{"period":"1month","weight":0.4238},{"period":"3month","weight":1.0301},{"period":"6month","weight":0.5849},{"period":"1year","weight":-0.1402},{"period":"ytd","weight":-0.0334}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nurix Therapeutics, Inc.于2009年8月27日在特拉华州成立。该公司是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为癌症和免疫紊乱的新治疗方法。利用他们在E3连接酶方面的广泛专业知识以及他们的专有DNA编码库，该公司已经建立了一个集成的发现平台DELigase，以识别和开发针对E3连接酶的新药物候选。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.063877},{"month":2,"riseRate":0.2,"avgChangeRate":-0.007659},{"month":3,"riseRate":0.2,"avgChangeRate":-0.071924},{"month":4,"riseRate":0.4,"avgChangeRate":-0.043438},{"month":5,"riseRate":0.4,"avgChangeRate":-0.000824},{"month":6,"riseRate":0.6,"avgChangeRate":0.118065},{"month":7,"riseRate":0.6,"avgChangeRate":0.085462},{"month":8,"riseRate":0.5,"avgChangeRate":0.016029},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.033904}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nurix Therapeutics(NRIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nurix Therapeutics(NRIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}